COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,722 Articles (22,913 medRxiv, 8,809 bioRxiv)

Most recent first Previous |  Page 86: Articles 851-860  | Next

Excitability as a Design Principle in the Immune System
Lebel, Y., Alon, U.
10.1101/2025.08.31.673412 — Posted: 2025-09-02
Determinants of Natural Killer Cell-Mediated Antibody Dependent Cellular Cytotoxicity in SARS-CoV-2 Antibodies
Depierreux, D. M., Ruiz, F. M., Lilly, M., Guenthoer, J., Chohan, V., Overbaugh, J.
10.1101/2025.08.28.672949 — Posted: 2025-08-29
Integrated phenotypic screening and chemical proteomics identifies ETF1 ligands that modulate viral translation and replication
Kim, A., Ma, K., Reinhardt, C. J., Lazar, D. C., Ogasawara, D., Shaw, T. M., de la Torre, J. C., Bailey, A. L., Melillo, B., Teijaro, J. R., Cravatt, B. F.
10.1101/2025.08.27.672717 — Posted: 2025-08-28
12-Lipoxygenase (12-LOX) Plays a Key Role in Hyperinflammatory Response Caused by SARS-CoV-2
D'silva, M., Vaughan, M. T., Maloney, D. J., Gupte, S. A., Nadler, J. L., Bakshi, C. S.
10.1101/2025.08.27.672781 — Posted: 2025-08-28
SARS-CoV-2 nucleocapsid induces hyperinflammation and vascular leakage through the Toll-like receptor signaling axis in macrophages
Yao, Z., Alvarez, P. A., Chavez, C., Delgado, Y., Kaushal, P., Austin, D., Li, Q., Yu, Y., Zaiss, A. K., Arumugaswami, V., Ding, Q., Hsu, J. J., Damoiseaux, R., Bouhaddou, M., Hoffmann, A., Li, M. M. H.
10.1101/2025.08.28.672752 — Posted: 2025-08-28
Morphological cell profiling for drug repurposing against SARS-CoV-2 infection
Asp, E., Rietdijk, J., Tampere, M., Axelsson, H., Njenda, D., Potdar, S., Kalman, A., Georgieva, P., Lapins, M., Ballante, F., Soler, A., De Kort, M., Aittokallio, T., Zaliani, A., Kuzikov, M., Gribbon, P., Lo, D., Carreras-Puigvert, J., Seashore-Ludlow, B., Spjuth, O., Ostling, P.
10.1101/2025.08.28.672794 — Posted: 2025-08-28
Affinity Maturation and Light-Chain-Mediated Paratope Diversification Anticipate Viral Evolution
Dingus, J., Yoo, D.-K., Kumar, S., Wang, Y., Kibria, M. G., Saghei, S., Chen, J. W., Caputo, N. M., Hwang, J., Chen, B., Wesemann, D. R.
10.1101/2025.08.27.672735 — Posted: 2025-08-28
Structural and functional analysis of VYD222: a broadly neutralizing antibody against SARS-CoV-2 variants
Yuan, M., West, B. R., Foreman, W. B., Powers, C., Feng, Z., Taylor, A. L., Yu, X., Wang, G., Walker, L., Starr, T. N., Allen, R., Wilson, I. A.
10.1101/2025.08.28.672883 — Posted: 2025-08-28
The Effect of SARS-COV-2 Protein Fragments onthe Dimerization of α-Synuclein
Coleman, L. M., Hansmann, U. H. E.
10.1101/2025.08.26.672456 — Posted: 2025-08-26
Polyfunctionality of broadly reactive non-neutralizing SARS-CoV-2 RBD antibodies
Rosenbaum, P., Planchais, C., Bruel, T., Beretta, M., Bolland, W., Staropoli, I., Guivel-Benhassine, F., Schwartz, O., Mouquet, H.
10.1101/2025.08.26.672080 — Posted: 2025-08-26

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).